Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,124
  • Shares Outstanding, K 162,019
  • Annual Sales, $ 6,150 K
  • Annual Income, $ -158,090 K
  • 60-Month Beta 1.79
  • Price/Sales 61.13
  • Price/Cash Flow N/A
  • Price/Book 2.23
Trade ADAP with:

Options Overview Details

View History
  • Implied Volatility 174.07% ( -55.88%)
  • Historical Volatility 78.92%
  • IV Percentile 86%
  • IV Rank 9.81%
  • IV High 1,176.02% on 05/16/22
  • IV Low 65.09% on 12/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 170
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 7,589
  • Open Int (30-Day) 7,226

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.38
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.64 +42.68%
on 07/15/22
2.40 -2.50%
on 08/05/22
+0.68 (+40.96%)
since 07/05/22
3-Month
1.26 +85.71%
on 05/12/22
2.40 -2.50%
on 08/05/22
+0.56 (+31.46%)
since 05/05/22
52-Week
1.26 +85.71%
on 05/12/22
6.86 -65.89%
on 09/10/21
-1.19 (-33.71%)
since 08/05/21

Most Recent Stories

More News
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

ADAP : 2.34 (+0.86%)
GTHX : 13.01 (+24.02%)
AXSM : 43.44 (+8.57%)
Why Adaptimmune Therapeutics Stock Is Popping Today

Buyout fever is sparking interest in the biotech's beaten-down shares today.

ADAP : 2.34 (+0.86%)
EPZM : 1.5200 (+2.70%)
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday

The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.

ADAP : 2.34 (+0.86%)
Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival,...

ADAP : 2.34 (+0.86%)
Adaptimmune Reports First Quarter Financial Results and Business Update

- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - -...

ADAP : 2.34 (+0.86%)
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to...

ADAP : 2.34 (+0.86%)
Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to...

ADAP : 2.34 (+0.86%)
New Strong Sell Stocks for April 26th

ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022

ALIM : 7.00 (+3.69%)
ANIK : 22.68 (-1.09%)
ADAP : 2.34 (+0.86%)
New Strong Sell Stocks for April 22nd

BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022

BBBY : 8.16 (+32.68%)
ADAP : 2.34 (+0.86%)
CLGN : 8.84 (+7.15%)
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today

Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.

ADAP : 2.34 (+0.86%)
AGEN : 2.65 (+3.52%)
SRNE : 2.76 (+2.22%)
REGN : 613.61 (-0.22%)
CMPI : 10.50 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 2.65
2nd Resistance Point 2.53
1st Resistance Point 2.43
Last Price 2.34
1st Support Level 2.21
2nd Support Level 2.09
3rd Support Level 1.99

See More

52-Week High 6.86
Fibonacci 61.8% 4.72
Fibonacci 50% 4.06
Fibonacci 38.2% 3.40
Last Price 2.34
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar